EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Intranasal Treatments for Children With Sleep-Disordered Breathing

Gillian M Nixon, Deborah Anderson, Alice Baker, Andrew Davidson, Amanda Griffiths, Anneke C Grobler, Gideon Pinczower, Joanne Rimmer, Elizabeth Rose, Chris J Selman, Catherine M Simpson, Moya Vandeleur und 1 weitere

JAMA Pediatrics · 2026

DOI: 10.1001/jamapediatrics.2025.5717 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Pediatrics, 2026. Verfasst von Gillian M Nixon und 12 weiteren Autor:innen. Beteiligte Einrichtung: Melbourne Children's Sleep Centre, Monash Children's Hospital, Monash Health, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Mometasone Furoate, Sleep Apnea Syndromes, Saline Solution, Glucocorticoids. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Symptoms of obstructive sleep apnea are common in childhood and associated with significant comorbidity. Surgical treatment with adenotonsillectomy is first-line treatment but medical treatments show potential to improve symptoms and reduce the need for surgery.

Objective

To determine the efficacy of 6 weeks of intranasal steroid (INS) compared with saline in children with obstructive sleep-disordered breathing (OSDB) with persistent symptoms after a 6-week intranasal saline run-in. Design, Setting, and Participants This was a double-blind, placebo-controlled, randomized clinical trial involving specialist clinic waitlists at 2 sites in Australia. Included were children aged 3 to 12 years. Study data were analyzed from January to June 2025.

Interventions

All children received once-daily intranasal saline for 6 weeks (run-in). Those with persisting symptoms (SDB score ≥−1) were randomized to either once-daily intranasal mometasone furoate, 50 µg, (INS) or continued saline for a further 6 weeks. Main Outcomes and Measures The primary outcome was symptom resolution (SDB score <−1). Secondary outcomes included behavior, quality of life, and parental perception of need for surgery. Analyses were adjusted for site and baseline measures.

Results

A total of 150 children (mean [SD] age, 6.2 [2.3] years; 93 male [62%]) were recruited. Of 139 children who completed the run-in phase, 41 (29.5%) had symptom resolution after saline run-in. Among 93 children randomized to intervention groups (47 INS; 46 saline), symptom resolution occurred in 35.6% (95% CI, 22.9%-50.6%) and 36.4% (95% CI, 23.5%-51.6%) of the INS and saline group, respectively, with no evidence for a clinically significant difference between groups (risk difference, −0.9%; 95% CI, −20.7% to 19.0%; P = .93). No group differences were found in secondary outcomes. Subgroup analysis did not reveal a group more or less likely to respond to medical treatment. Conclusions and Relevance Results of this randomized clinical trial show that 6 weeks of intranasal saline resolved OSDB symptoms in nearly one-third of children. An additional 6-week course of INS or saline led to resolution in another one-third (total resolution around 50%), with no added benefit from INS. Intranasal saline is an effective short-term first-line treatment for OSDB before consideration of polysomnography or surgical intervention. Results suggest that saline should be recommended for 3 months before assessing the need for specialist referral. Trial Registration ClinicalTrials.gov Identifier: NCT05382494

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mometasone FuroateSleep Apnea SyndromesSaline SolutionGlucocorticoidsHumansMaleAdministration, IntranasalChildChild, PreschoolDouble-Blind MethodFemaleTreatment OutcomeQuality of Life

Substanzen

Mometasone FuroateSaline SolutionGlucocorticoids

Autor:innen und Institutionen

  • Melbourne Children's Sleep Centre, Monash Children's Hospital, Monash Health, Melbourne, Victoria, Australia.
  • Department of Paediatrics, Monash University, Melbourne, Victoria, Australia.
  • Population Allergy, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
  • Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.
  • Department of General Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia.
  • Anaesthetics and Pain, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.

Zitieren

APA

Nixon, G. M., Anderson, D., Baker, A., Davidson, A., Griffiths, A., Grobler, A. C., Pinczower, G., Rimmer, J., Rose, E., Selman, C. J., Simpson, C. M., Vandeleur, M., & Perrett, K. P. (2026). Intranasal Treatments for Children With Sleep-Disordered Breathing. JAMA Pediatrics. https://doi.org/10.1001/jamapediatrics.2025.5717

Vancouver

Nixon GM, Anderson D, Baker A, Davidson A, Griffiths A, Grobler AC, et al. Intranasal Treatments for Children With Sleep-Disordered Breathing. JAMA Pediatrics. 2026. doi:10.1001/jamapediatrics.2025.5717

BibTeX
@article{Nixon2026,
  author = {Nixon, Gillian M and Anderson, Deborah and Baker, Alice and Davidson, Andrew and Griffiths, Amanda and Grobler, Anneke C and Pinczower, Gideon and Rimmer, Joanne and Rose, Elizabeth and Selman, Chris J and Simpson, Catherine M and Vandeleur, Moya and Perrett, Kirsten P},
  title = {Intranasal Treatments for Children With Sleep-Disordered Breathing},
  journal = {JAMA Pediatrics},
  year = {2026},
  doi = {10.1001/jamapediatrics.2025.5717}
}
Kostenlos starten →